# OnCo record paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013" ;
  schema:name "Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer"@en ;
  schema:description "Screening 424 women with ER-negative breast cancer found androgen receptor in 12%; the prostate drug bicalutamide held the disease stable for six months in 19% of them, the first clinical proof that the LAR subtype can be treated through its receptor."@en ;
  schema:url <https://onco.cc/key-papers/paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1158/1078-0432.CCR-12-3327>, <https://pubmed.ncbi.nlm.nih.gov/23965901/> ;
  schema:sameAs <https://doi.org/10.1158/1078-0432.CCR-12-3327> ;
  schema:datePublished "2013"^^xsd:gYear ;
  schema:author "Gucalp A, Tolaney S, Isakoff SJ, et al." ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/bicalutamide/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/> ;
  onco:pathways <https://onco.cc/pathways/ar-signaling/> ;
  onco:terms <https://onco.cc/terms/ihc/> ;
  onco:people <https://onco.cc/people/sara-tolaney/>, <https://onco.cc/people/hope-rugo/> ;
  onco:journals <https://onco.cc/journals/clinical-cancer-research/> .